ITMN Share Price

Open 0.00 Change Price %
High 0.00 1 Day 0.00 0.00
Low 0.00 1 Week 0.00 0.00
Close 73.89 1 Month 0.00 0.00
Volume 5169 1 Year 0.00 0.00
52 Week High 174.10
52 Week Low 0.00
ITMN Important Levels
Resistance 2 73.89
Resistance 1 73.89
Pivot 24.63
Support 1 73.89
Support 2 73.89
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
APRI 2.86 89.40%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
APRI 2.86 89.40%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
SKBI 0.12 50.00%
UNXL 1.69 34.13%
LIFE 3.25 32.65%
CHCI 2.42 29.41%
GLBS 6.17 27.22%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

InterMune, Inc. (NASDAQ: ITMN)

ITMN Technical Analysis 5
As on 26th Sep 2014 ITMN Share Price closed @ 73.89 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 32.99 & Strong Buy for SHORT-TERM with Stoploss of 57.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
ITMN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ITMN Other Details
Segment EQ
Market Capital 537745792.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.intermune.com
ITMN Address
ITMN
3280 Bayshore Boulevard
Brisbane, CA 94005
United States
Phone: 415-466-2200
Fax: 415-466-2300
ITMN Latest News
Ex-InterMune Exec Says Salman Voids Insider Trading Loss   Law360 (subscription)   - 14th Dec 16
After big sale to Roche, InterMune boss jumps to venture capital   San Francisco Business Times (blog)   - 09th Jan 15
4 winners, 3 losers in Roche's $8.3 billion takeover of InterMune   San Francisco Business Times (blog)   - 03rd Sep 14
Roche Holding Agrees to Buy InterMune for $8.3 Billion   Bloomberg   - 24th Aug 14
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights   PR Newswire (press release)   - 07th Aug 14
Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune ...   Motley Fool   - 18th Mar 14
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic ...   PR Newswire (press release)   - 25th Feb 14
AbbVie, InterMune Sue to Block Clinical-Trial Data Release   Bloomberg   - 11th Mar 13
Ex-InterMune CEO Harkonen's Wire-Fraud Conviction Upheld   Bloomberg   - 05th Mar 13
InterMune to Divest Actimmune┬« (Interferon Gamma-1b)   PR Newswire (press release)   - 22nd May 12
Interactive Technical Analysis Chart InterMune, Inc. ( ITMN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on InterMune, Inc.
ITMN Business Profile
InterMune, Inc. (InterMune), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, the Company began the commercial launch of Esbriet in Canada. June 19, 2012, the Company completed the divestiture of its worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by the Company under the tradename Actimmune. On June 19, 2012, the Company sold the rights of Actimmune (interferon gamma-1b) to Vidara Therapeutics International Limited.